Case-crossover study design in pharmacoepidemiology: Systematic review and recommendations

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 11, 2013, Pages 1146-1153

  Consiglio, Giulia P ^a   Burden, Andrea M ^a   Maclure, Malcolm ^b   Mccarthy, Lisa ^a,c   Cadarette, Suzanne M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Case crossover; Case only; Pharmacoepidemiology; Review literature as topic

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; PSYCHOTROPIC AGENT; VACCINE;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMBASE; FALLING; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MEDLINE; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PUBLICATION; RESPIRATORY TRACT DISEASE; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TRAFFIC ACCIDENT;

CASE-CROSSOVER; CASE-ONLY; PHARMACOEPIDEMIOLOGY; REVIEW LITERATURE AS TOPIC;

CROSS-OVER STUDIES; EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN;

EID: 84886244768     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3508     Document Type: Review

References (115)

1. Rothman KJ. Epidemiology: An Introduction (2nd edn). Oxford University Press Inc: New York, NY, 2012; pp. 268.
2. Strom B, Kimmel SE. Textbook of Pharmacoepidemiology. John Wiley & Sons Inc West Sussex: England, 2006; pp. 520.
3. Harpe S. Study Designs for Pharmacoepidemiology. In Understanding Pharmacoepidemiology, Yang Y, West-Strum D (eds.). McGraw-Hill Companies: United States of America, 2011; pp. 39-54.
4. Our questions, our decisions: standards for patient-centered outcomes research, in Public comment draft report of the Patient-Centered Outcomes Research Institute (PCORI) 2012: PCORI Methodology Committee.
5. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
6. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193-221.
7. Maclure M, Mittleman MA. Case-crossover designs compared with dynamic follow-up designs. Epidemiology 2008; 19: 176-178.
8. Maclure M, Fireman B, Nelson JC, Hua W, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf 2012; 21: 50-61.
9. Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology 1996; 7: 231-239.
10. Tadrous M, Gagne JJ, Stürmer T, Cadarette SM. Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf 2013; 22: 122-129.
11. Carracedo-Martinez E, Tobias A, Saez M, Taracido M, et al. Case-crossover design: basic essentials and applications. Gac Sanit 2009; 23: 161-165.
12. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res 2009; 18: 53-65.
13. DiPietro NA. Methods in epidemiology: observational study designs. Pharmacother 2010; 30: 973-984.
14. Ellenberg S, Braun, MM. Monitoring the safety of vaccines-assessing the risks. Drug Saf 2002; 25: 145-152.
15. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996; 143: 1165-1173.
16. Figueiras A, Tato F, Takkouche B, GestalOtero JJ. An algorithm for the design of epidemiologic studies applied to drug surveillance. Eur J Clin Pharmacol 1997; 51: 445-448.
17. Gagne JJ, Fireman B, Ryan PB, Maclure M, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf 2012; 21: 32-40.
18. Hanley J, Dendukuri, N. Efficient sampling approaches to address confounding in database studies. Stat Methods Med Res 2009; 18: 81-105.
19. Lee CH, Wang JD, Chen PC. Case-crossover design: an alternative strategy for detecting drug-induced liver injury. J Clin Epidemiol 2012; 65: 560-567.
20. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, et al. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 1998; 7: 275-280.
21. Nicholas JM, Grieve AP, Gulliford MC. Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designs. J Clin Epidemiol 2012; 65: 384-393.
22. Quartey G, Feudjo-Tepie M, Wang JX, Kim J. Opportunities for minimization of confounding in observational research. Pharm Stat 2011; 10: 539-547.
23. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007; 82: 143-156.
24. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-868.
25. Schneeweiss S, Avorn, J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337.
26. Tsai CL, Camargo, CA Jr. Methodological considerations, such as directed acyclic graphs, for studying 'acute on chronic' disease epidemiology: chronic obstructive pulmonary disease example. J Clin Epidemiol 2009; 62: 982-90.
27. Varadhan R, Frangakis, CE. Revealing and addressing length bias and heterogeneous effects in frequency case-crossover studies. Am J Epidemiol 2004; 159: 596-602.
28. Wang PS, Schneeweiss S, Glynn RJ, Mogun H, et al. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol 2004; 14: 296-303.
29. Etminan M, Gill S, FitzGerald M, Samii A. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making. J Clin Pharmacol 2006; 46: 6-9.
30. Etminan M, Samii, A. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs. Pharmacother 2004; 24: 964-969.
31. Klungel OH, Martens EP, Psaty BM, Grobbee DE, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004; 57: 1223-1231.
32. Luo X, Sorock GS. Analysis of recurrent event data under the case-crossover design with applications to elderly falls. Stat Med 2008; 27: 2890-2901.
33. Orriols L, Salmi LR, Philip P, Moore N, et al. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf 2009; 18: 647-658.
34. Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 2009; 104: 1298-1313.
35. Smeeth L, Donnan PT, Cook DG. The use of primary care databases: Case-control and case-only designs. Fam Pract 2006; 23: 597-604.
36. Wu L, Anthony, JC. The use of the case-crossover design in studying illicit drug use. Subst Use Misuse 2000; 35: 1035-1050.
37. Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, et al. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3: 459-465.
38. Andersen SS, Hansen ML, Gislason GH, Schramm TK, et al. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace 2009; 11: 886-891.
39. Azoulay L, Blais L, Koren G, LeLorier J, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry 2008; 69: 526-532.
40. Barbone F, McMahon AD, Davey PG, Morris AD, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331-1336.
41. Berard A, Azoulay L, Nakhai-Pour HR, Moussally K. Isotretinoin and the risk of cardiovascular, cerebrovascular and thromboembolic disorders. Dermatology 2011; 223: 45-51.
42. Berry SD, Mittleman MA, Zhang Y, Solomon DH, et al. New loop diuretic prescriptions may be an acute risk factor for falls in the nursing home. Pharmacoepidemiol Drug Saf 2012; 21: 560-563.
43. Berry SD, Zhang Y, Lipsitz LA, Mittleman MA, et al. Antidepressant prescriptions: an acute window for falls in the nursing home. J Gerontol A Biol Sci Med Sci 2011; 66: 1124-1130.
44. Biskupiak JE, Brixner DI, Howard K, Oderda GM. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Pall Care Pharmacother 2006; 20: 7-14.
45. Chang CH, Chen HC, Lin JW, Kuo CW, et al. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: A nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 763-771.
46. Chang CH, Shau WY, Kuo CW, Chen ST, et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010; 41: 1884-1890.
47. Chang CH, Lin JW, Chen HC, Kuo CW, et al. Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut 2011; 60: 1372-1378.
48. Choi NK, Chang Y, Jung SY, Choi YK, et al. A population-based case-crossover study of polyethylene glycol use and acute renal failure risk in the elderly. World J of Gastroenterol 2011; 17: 651-656.
49. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, et al. Drug exposure and psoriasis vulgaris: Case-control and case-crossover studies. Acta Derm Venereol 2005; 85: 299-303.
50. Confavreux C, Suissa S, Saddier P, Bourdes V, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001; 344: 319-326.
51. Corrao G, Zambon A, Faini S, Bagnardi V, et al. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol 2005; 58: 92-97.
52. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7: 1314-1321.
53. Duran-Barragan S, McGwin G, Jr., Vila LM, Reveille JD, et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 2008; 47: 1093-1096.
54. Etienney I, Beaugerie L, Viboud C, Flahault A. Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study. Gut 2003; 52: 260-263.
55. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Aids 2001; 15: 1843-1848.
56. Finkelstein Y, Schechter T, Garcia-Bournissen F, Kirby M, et al. Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study. Clin Ther 2007; 29: 2738-2743.
57. Fosbol EL, Folke F, Jacobsen S, Rasmussen JN, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Res 2010; 3: 395-405.
58. France EK, Glanz JM, Xu S, Davis RL, et al. Safety of the trivalent inactivated influenza vaccine among children-A population-based study. Arch Pediatr Adolesc Med 2004; 158: 1031-1036.
59. Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther 2010; 88: 347-353.
60. Garrison MM, Lozano P, Christakis DA. Controller medication use and sleep problems in pediatric asthma: a longitudinal case-crossover analysis. Arch Pediatr Adolesc Med 2011; 165: 826-830.
61. Gibson JE, Hubbard RB, Smith CJP, Tata LJ, et al. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol 2009; 169: 761-768.
62. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circ Res 2006; 113: 2906-2913.
63. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Int Med 2009; 169: 141-149.
64. Grimaldi-Bensouda L, Abenhaim L, Michaud L, Mouterde O, et al. Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study. Eur J Clin Pharmacol 2010; 66: 831-837.
65. Hallas J, Bjerrum L, Stovring H, Andersen M. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol 2008; 168: 966-973.
66. Hambidge SJ, Glanz JM, France EK, McClure D, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 2006; 296: 1990-1997.
67. Handoko KB, Zwart-van Rijkom JEF, Hermens WAJJ, Souverein PC, et al. Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study. Pharmacoepidemiol Drug Saf 2007; 16: 189-196.
68. Hauser T, Mahr A, Metzler C, Coste J, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 2008; 63: 677-682.
69. Hebert C, Delaney JAC, Hemmelgarn B, Levesque LE, et al. Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs. Pharmacoepidemiol Drug Saf 2007; 16: 845-849.
70. Hernandez-Diaz S, Hernan MA, Meyer K, Werler MM, et al. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol 2003; 158: 385-391.
71. Hunter DJ, York M, Chaisson CE, Woods R, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33: 1341-1345.
72. Jung SY, Choi NK, Kim JY, Chang Y, et al. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurol 2011; 77: 1229-1234.
73. Ki M, Park T, Yi SG, Oh JK, et al. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Am J Epidemiol 2003; 157: 158-165.
74. Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, et al. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study. Pharmacoepidemiol Drug Saf 2011; 20: 914-921.
75. Lee CH, Wang JD, Chen PC. Case-crossover study of hospitalization for acute hepatitis in Chinese herb users. J Gastroenterol Hepatol 2008; 23: 1549-55.
76. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf 2010; 19: 708-714.
77. Lee CH, Wang JD, Chen PC. Risk of liver injury associated with Chinese herbal products containing radix bupleuri in 639, 779 patients with hepatitis B virus infection. PLoS One 2011; 6: e16064.
78. Lee YC, Chang CH, Lin JW, Chen HC, et al. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int 2012; 32: 859-866.
79. Martins IS, Pellegrino FLPC, Freitas AdA, Santos MdS, et al. Case-crossover study of Burkholderia cepacia complex bloodstream infection associated with contaminated intravenous bromopride. Infect Control Hosp Epidemiol 2010; 31: 516-521.
80. Meuleners LB, Duke J, Lee AH, Palamara P, et al. Psychoactive medications and crash involvement requiring hospitalization for older drivers: a population-based study. J Am Geriatr Soc 2011; 59: 1575-1580.
81. Mittleman MA, MacLure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with Sildenafil Citrate. Am J Cardiol 2005; 96: 443-446.
82. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS One 2008; 3: e2522.
83. Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002; 11: 97-104.
84. Olesen JB, Hansen PR, Erdal J, Abildstrom SZ, et al. Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol Drug Saf 2010; 19: 518-524.
85. Orriols L, Delorme B, Gadegbeku B, Tricotel A, et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med 2010; 1-10.
86. Orriols L, Philip P, Moore N, Castot A, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 2011; 89: 595-601.
87. Park T, Ki M, Yi SG. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Stat Med 2004; 23: 1871-1883.
88. Ray WA, Fought RL, Decker MD. Psychoactive-drugs and the risk of injurious motor-vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136: 873-883.
89. Rifkin SB, Smith MR, Brotman RM, Gindi RM, et al. Hormonal contraception and risk of bacterial vaginosis diagnosis in an observational study of women attending STD clinics in Baltimore, MD. Contraception 2009; 80: 63-67.
90. Risselada R, Straatman H, van Kooten F, Dippel DWJ, et al. Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage. J Thromb Haemost 2011; 9: 517-523.
91. Rogers MAM, Levine DA, Blumberg N, Flanders SA, et al. Triggers of hospitalization for venous thromboembolism. Circ Res 2012; 125: 2092-2099.
92. Schelleman H, Bilker WB, Brensinger CM, Han X, et al. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: Interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008; 84: 581-588.
93. Schelleman H, Bilker WB, Brensinger CM, Wan F, et al. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010; 88: 214-222.
94. Seitz DP, Campbell RJ, Bell CM, Gill SS, et al. Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults. J Clin Psychopharmacol 2012; 32: 403-407.
95. Shau WY, Chen HC, Chen ST, Chou HW, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): A case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord 2012; 12: 4.
96. Shuto H, Imakyure O, Matsumoto J, Egawa T, et al. Medication use as a risk factor for inpatient falls in an acute care hospital: A case-crossover study. Br J Clin Pharmacol 2010; 69: 535-542.
97. Sode J, Obel N, Hallas J, Lassen A. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol 2007; 63: 499-503.
98. Sturkenboom M, Middelbeek A, De Jong Van den Berg L, Van den Berg P, et al. Vulvo-vaginal candidiasis associated with acitretin. J Clin Epidemiol 1995; 48:991-997.
99. Teixeira L, Mouthon L, Mahr A, Berezne A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-116.
100. Toh S, Mitchell AA, Anderka M, de Jong-van den Berg LTW, et al. Antibiotics and oral contraceptive failure-a case-crossover study. Contraception 2011; 83: 418-425.
101. Velthove KJ, Leufkens HGM, Schweizer RC, Van Solinge WW, et al. Medication changes prior to hospitalization for obstructive lung disease: a case-crossover study. Ann Pharmacother 2010; 44: 267-273.
102. Smith S, Sato M, Gore SD, Baer MR, et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematol 2012; 97: 15-20.
103. Wright AJ, Gomes T, Mamdani MM, Horn JR, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. Can Med Assoc J 2011; 183: 303-307.
104. Wu CS, Wang SC, Cheng YC, Gau SSF. Association of cerebrovascular events with antidepressant use: A case-crossover study. Am J Psychiatr 2011; 168: 511-521.
105. Yang YH, Lai JN, Lee CH, Wang JD, et al. Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: a case-crossover study. J Epidemiol 2011; 21: 37-43.
106. Zambon A, Polo Friz H, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 2009; 32: 159-167.
107. Selby J, Beal A, Frank L. The patient-centered outcomes research institute (PCORI) national priorities for research and initial research agenda. JAMA 2012; 307: 1583-1584.
108. Suissa S, Henry, D. The establishment of the Canadian network for observational drug effect studies (cNODES). Pharmacoepidemiol Drug Saf 2011; 20: S168.
109. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253-259.
110. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2011; 82: 143-156.
111. National Pharmaceutical Council. A brief history of comparative effectiveness research and evidence-based medicine 2011: Washington DC: National Pharmaceutical Council. http://www.npcnow.org/system/files/research/download/CER_toolkit_NPC_2010.pdf.
112. Stürmer T, Joshi M, Glynn RJ, Avorn J, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59: 437-447.
113. Paterson JM, Laupacis A, Bassett K, Anderson GM, et al. Using Pharmacoepidemiology to inform drug coverage policy: initial lessons from a two-province collaborative. Health Aff 2006; 25: 1436-1443.
114. Suissa S. The case-time-control design. Epidemiology 1995; 6: 248-253.
115. Nordmann S, Biard L, Ravaud P, Esposito-Farese M, et al. Case-only designs in pharmacoepidemiology: a systematic review. PLoS One 2012; 7: e49444.